IP Library Granted Patent US 11,026,913
Granted Patent B2
US 11,026,913 · App. 14/916,634 · Granted Jun 8, 2021

Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto

Inventor: Claudia R. Morris (Atlanta, GA)
Assignees: Emory University; Children's Healthcare of Atlanta, Inc.
A61K31/23A23L33/12A23L33/135A23L33/15A23L33/155A23L33/16A23L33/175A23L33/40A61K9/0056A61K31/047A61K31/07A61K31/122A61K31/19A61K31/20A61K31/202A61K31/205A61K31/22A61K31/231A61K31/232A61K31/355A61K31/375A61K31/385A61K31/4375A61K31/473A61K31/59A61K31/661A61K31/7004A61K33/18A61K33/24A61K33/26A61K33/30A61K33/32A61K33/34A61K33/42A61K35/741A61K38/46A61K45/06A23V2002/00A61K9/145A61K9/2013A61K9/4858A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,026,913
App. No.
14/916,634
Granted
Jun 8, 2021
Kind
B2
Abstract

This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium 5 chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.

Claims (27)

1. A method of treating autism spectrum disorder comprising orally administering daily to a subject diagnosed with an autism spectrum disorder, apraxia, and a gastrointestinal tract impairment, an effective amount of a dietary formulation comprising:

a) a medium chain fatty acid, glycerol ester, or alkyl ester thereof,

b) an omega-3 fatty acid, glycerol ester, or alkyl ester thereof,

c) an omega-6 fatty acid, glycerol ester, or alkyl ester thereof, and

d) a vitamin E isomer from 100 mg to 10,000 mg,

e) 5-hydroxytryptophan, from 10 mg to 100 mg,

f) sulforaphane from 500 micrograms to 5000 micrograms, and

g) curcumin from 50 mg to 2500 mg; and

wherein the dietary formulation comprises less than 2% long chain saturated fatty acids by weight of the total weight of fatty acids.

2. The method of claim 1 , wherein the gastrointestinal tract impairment is intestinal lymphangiectasia.

3. The method of claim 1 , wherein the gastrointestinal tract impairment is maldigestion.

4. The method of claim 1 , wherein the gastrointestinal tract impairment is malabsorption.

5. The method of claim 1 , wherein the gastrointestinal tract impairment is small intestinal bacterial overgrowth.

6. The method of claim 1 , wherein the subject is a sub-adult from 12 months to 19 years of age.

7. The method of claim 6 , wherein the sub-adult is from about 12 months of age to about 3 years of age.

8. The method of claim 6 , wherein the sub-adult is from 3 years of age to 5 years of age.

9. The method of claim 6 , wherein the sub-adult is 5 years of age to 9 years of age.

10. The method of claim 6 , wherein the sub-adult is 9 years of age to 12 years of age.

11. The method of claim 6 , wherein the sub-adult is 13 years of age to 19 years of age.

12. The method of claim 1 , wherein the medium chain fatty acid or alkyl ester thereof is capric acid, ethyl caprate, caprylic acid, ethyl caprylate, hexanoic acid, ethyl hexanoate, or combinations thereof.

13. The method of claim 1 , wherein the dietary formulation further comprises a vitamin K.

14. The method of claim 1 , wherein the omega-3 fatty acid or alkyl ester thereof is alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, ethyl linolenate, ethyl eicosapentaenoate, ethyl docosahexaenoate, or combinations thereof.

15. The method of claim 1 , wherein the omega-3 fatty acid contains eicosapentaenoic acid and docosahexaenoic acid.

16. The method of claim 15 , wherein a ratio of eicosapentaenoic acid and docosahexaenoic acid is in a range of from about 1.5:1 to about 5:1.

17. The method of claim 1 , wherein the vitamin E isomer is alpha-tocopherol, gamma-tocopherol, or a combination thereof.

18. The method of claim 1 , wherein the omega-6 fatty acid is gamma-linolenic acid.

19. The method of claim 1 , wherein the dietary formulation comprises less than 1% long chain saturated fatty acids by weight of the total weight of fatty acids.

Continuity (2)
Provisional Application 61873865 · Sep 5, 2013
Related Publication 20160199337A1 · Jul 14, 2016